Trade Omnicell - OMCL CFD

Trading Conditions

• Spread: 0.14
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 27.09
• Open: 27.17
• 1-Year Change: -55.17%
• Day's Range: 27.17 - 28.17

Omnicell Company profile

About Omnicell, Inc.

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. Its point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. Its Central Pharmacy IV Compounding Service offers a comprehensive service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Omnicell, Inc. revenues increased 27% to $1.13B. Net income increased from $32.2M to $77.8M. Revenues reflect Connected devices, software licenses, and other segment increase of 32% to $739.1M, SaaS, subscription software, and technology-enabled services segment increase from $53.8M to $112.5M, United States segment increase of 28% to $1.02B, Rest of the World segment increase of 18% to $111.2M.

Equity composition

Common Stock $.001 Par, 12/10, 100M auth., 37,148,706 issd. 4,121,123 shs. in Treas. @$65.1M. Insiders own 2.25%. Initial Public Offering: 8/07/01, 6Mshares @ $7 by U.S. Bancorp Piper Jaffray. 7/01 1-for-1.6 stock split. *NOTE: 8/01, the Company changed it's name from Omnicell.com.